Home › Left Ventricular Hypertrophy › NCT05388032
Sodium Lowering Vascular Effects Trial
A Mechanistic Trial of Dietary Sodium Reduction on Vascular Structure and Function
Who can join
Ages 40 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Men or women aged ≥40 years. Individuals \<40 years are at a low risk for clinical and subclinical CVD * Elevated BP or hypertension (systolic BP ≥120 mmHg and diastolic BP ≥80 mmHg with or without use of antihypertensive medications) Exclusion Criteria: * Glomerular filtration rate (eGFR) \<30 or end-stage renal disease (kidney transplant or chronic dialysis) * History of cardiovascular disease * Shift worker or regularly work at night * Cancer requiring chemotherapy or radiation treatment in the previous two years * Current pregnancy or breastfeeding or plans to become pregnant during the study * Consumption of ≥21 alcoholic drinks/week * Current participation in another lifestyle intervention or drug trial * Current residence or planned residence that makes it difficult to meet trial requirements * Other concerns regarding ability to meet trial requirements (at the discretion of the study coordinator)
About the study
The proposed mechanistic trial will test the effect of dietary sodium reduction on cardiac and vascular structure and function in those with elevated blood pressure or hypertension. Findings from this study will fill the knowledge gap on the underlying mechanisms of dietary sodium intake on cardiovascular disease risk in addition to blood pressure and could provide further evidence on sodium reduction for the prevention of cardiovascular disease.
What is being tested
- Sodium Reduction Intervention (behavioral)
Sponsor: Tulane University · Participants: 256 · Started: Jan 25, 2023
Contact the study team
- Marigny Bostock, MA, CHES · Phone: 504-988-4391
Official record on ClinicalTrials.gov — NCT05388032
Locations in the U.S.
| Louisiana | Tulane University Office of Health Research, New Orleans |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.